Physician profile
Lorenza Freddo
NPI 1427013135
$5,466.49
in general payments reported to CMS, 2019-2025
20 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $589 · 2021: $1,101 · 2022: $1,218 · 2023: $739 · 2024: $624 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,405.51 | 2021-2025 | |
| Biogen, INC. | $508.75 | 2019-2023 | Vumerity, Tysabri |
| Novo Nordisk INC | $412.74 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $375.11 | 2019-2024 | |
| Scilex Pharmaceuticals INC. | $331.00 | 2020-2024 | Ztlido |
| Emd Serono, INC. | $181.21 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $170.70 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $153.14 | 2022 | |
| Acorda Therapeutics, INC | $149.50 | 2019 | |
| Genentech USA, INC. | $146.66 | 2019 | |
| Genzyme Corporation | $141.81 | 2019-2022 | |
| Allergan, INC. | $131.56 | 2020 | |
| Amgen INC. | $99.80 | 2019-2025 | Uplizna |
| Collegium Pharmaceutical, INC. | $70.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.50 | 2019-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $47.78 | 2019 | |
| Avanir Pharmaceuticals, INC. | $34.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.75 | 2021 | |
| Redhill Biopharma INC. | $13.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorenza Freddo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.